TapImmune to Present at 2018 NYC Oncology Investor Conference

JACKSONVILLE, Florida, May  7, 2018 – TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced that its President and CEO, Peter Hoang, will give a company presentation at the 2018 NYC Oncology Investor Conference, held May 8-9, 2018 at Wilson Sonsini Goodrich & Rosati in New York City.

 

Presentation Details

Date: Wednesday, May 9th, 2018

Time: 3:00 PM ET[/vc_column_text][vc_empty_space height=”4px”][vc_column_text][pr-disclaimer]